NCT02956850 - A Study in Healthy Volunteers and in Participants With Chronic Hepatitis B to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7020531 | Biotech Hunter

Enrollment

160

Participants

Timeline

Start Date

December 12, 2016

Primary Completion Date

June 15, 2021

Study Completion Date

June 15, 2021

Conditions

Hepatitis B, Chronic

Interventions

OTHER

Placebo

Placebo matching to RO7020531 will be administered as per schedule specified in the respective arm.

DRUG

RO7020531

RO7020531 will be administered as per schedule specified in the respective arm.

Trial Locations (18)

112

Taipei Veterans General Hospital, Taipei

333

Chang Gung Memorial Hospital, Taoyuan District

1142

Auckland Clinical Studies, Auckland

1407

Gastroenterology department, Second clinic of internal diseases, Sofia

1612

COMAC Medical; Clinical Research Unit for Phase I, Sofia

10330

King Chulalongkorn Memorial Hospital, Bangkok

10700

Siriraj Hospital, Bangkok

20089

Medicina Generale ed Epatologia (Humanitas-Rozzano), Rozzano

24127

ASST PAPA GIOVANNI XXIII; Epatologia e gastroenterologia pediatrica e dei trapianti, Bergamo

40705

Taichung Veterans General Hospital, Xitun Dist.

41124

Azienda Ospedaliero Universitaria Di Modena Policlinico; U.O. Farmacia, Modena

50200

Maharaj Nakorn Chiang Mai Hospital, Chiang Mai

70457

National Cheng Kung University Hospital, Tainan City

123456

The Chinese University of Hong Kong, Shatin

999077

Queen Mary Hospital, Hong Kong

1100 DD

Academisch Medisch Centrum Universiteit Amsterdam; Dermatology and VU University Medical Center, Amsterdam

L7 8XP

Royal Liverpool University Hospital, Liverpool

SE5 9RS

King College Hospital NHS Foundation Trust, London

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY